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This first issue of 2019 has been assembled to honor Prof. 
Elias (Eli) Michaelis, in the tradition of special issues of 
Neurochemical Research dedicated in honor of outstand‑
ing neurochemists. This issue includes various topics that 
have been related to Eli’s research areas: glutamate neuro‑
transmission and metabolism, mitochondrial function, cal‑
cium regulation, oxidative stress in aging, alcoholism, and 
neurodegeneration.
It is difficult to find words that are superlative enough 
to describe Eli whose outstanding career in the areas of 
leadership, teaching, research, and service have spanned a 
myriad of roles and research topics, and who enjoys high 
esteem among his colleagues. Eli truly exemplifies what it 
means to be a visionary, a leader, an academician, a profes‑
sor, a scientist, and a mentor. Having devoted more than 
45 years to science at the University of Kansas since 1973, 
Eli’s steady and unflinching passion for science has led him 
to pursue a broad range of research areas in neurochem‑
istry, cell and molecular neurobiology, pharmacology and 
toxicology.
He is the recipient of numerous prestigious awards, 
including a special fellowship by the National Institute 
on Neurological Diseases and Stroke that allowed him to 
transition from clinical medicine to experimental neuro‑
chemistry, a MERIT award from the National Institute on 
Alcoholism and Alcohol Abuse, the Higuchi Award for 
Biomedical Sciences at the University of Kansas, and a 
Distinguished Alumnus Award from St. Louis University 
School of Medicine. His commitment to service has led him 
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to serve in many roles in the academic and scientific com‑
munity, including as department chair and as director of a 
multidisciplinary research center at the University of Kan‑
sas. He has served on and chaired numerous scientific review 
committees at the National Institutes of Health, the Veterans 
Administration Merit Awards, and the Alzheimer’s Disease 
Drug Discovery Foundation. In recognition of his scientific 
work the University of Kansas named him a University Dis‑
tinguished Professor. Eli has maintained continuous funding 
for his research over a period of 45 years, including several 
multi‑investigator research programs. This has allowed him 
to devote himself to training graduate students, postdoc‑
toral fellows, and faculty with the aim of building a strong 
foundation for their careers and research goals, and many of 
them have gone on to successful careers as highly respected 
scientists.
Eli was born and raised in Sudan and almost followed in 
his father’s footsteps as a physician. He entered the St. Louis 
University School of Medicine where he received his M.D. 
degree in 1969. After graduation and while serving in the 
United States Public Health Service in Kentucky, he initiated 
a research project at the University of Kentucky on the char‑
acterization of the molecular properties of glutamate recep‑
tors in the central nervous system. He received his Ph.D. in 
1973 from the University of Kentucky School of Medicine 
in Physiology and Biophysics and he took a position as an 
Assistant Professor at the University of Kansas.
At a time when there were practically no chemical tools 
to activate or inhibit glutamate receptors, Eli and his stu‑
dents and post‑docs published a series of studies on the 
extraction from plasma membranes, isolation, and recon‑
stitution of proteins with glutamate‑binding characteristics 
expected of receptors. He and his colleagues continued 
these efforts over the years leading to the development of 
immunochemical tools that led to the cloning of the cDNA’s 
of four proteins forming a complex with the binding sites 
and ion conductance similar to those of NMDA glutamate 
receptors, Together with his wife, Mary Michaelis, he also 
worked on biochemical measurements of calcium regulat‑
ing enzyme (ATPase) and transport carrier (sodium‑calcium 
exchanger) activities in isolated synaptic plasma membrane 
preparations as calcium fluxes play such a crucial role in 
glutamate receptor signaling. Mary Michaelis has continued 
and greatly expanded this line of neurochemical research in 
calcium regulation.
Glutamate neurotransmission was the very first topic that 
drew Eli to neurochemical investigations and inspired his 
tireless efforts to understand the biochemical events asso‑
ciated with glutamate signaling and the effects of alcohol 
intake, oxidative stress, and aging on this signaling in the 
central nervous system. To probe further the regulation of 
glutamate activity in the brain, Eli and his colleagues in 
more recent years, focused on glutamate metabolism and 
the role of the enzyme glutamate dehydrogenase on syn‑
aptic glutamate activity. Having generated transgenic mice 
that overexpress this enzyme in brain neurons only, Eli has 
shown the importance of this enzyme in maintaining the 
levels of releasable glutamate in neurons, and the effects that 
it has on synaptic transmission, neuronal synapse structure, 
and neuronal survival during aging, In addition, Eli and his 
colleagues have explored the gene expression patterns most 
affected by the overexpression of glutamate dehydrogenase 
and the changes in such patterns throughout the lifespan. As 
is apparent, starting from the point of trying to understand 
how glutamate may function in the brain at the molecular 
level, Eli has made substantial contributions to neurochem‑
istry across a range of research areas, including his notable 
and pioneering work on the effects of alcoholism on gluta‑
mate neurotransmission, as well as the effects of altered glu‑
tamate metabolism in increased resistance to brain ischemia. 
His transgenic mouse model with an excess generation of 
glutamate in neurons has contributed to our understanding 
of the role of glutamate in the aging brain and led him to 
the study of Alzheimer’s disease as he extended his focus to 
mitochondrial metabolism and genetic and genomic studies 
of mitochondrial DNA.
Throughout his career, Eli maintained close professional 
and personal relationships with many scientists around the 
world and was appreciated by many of us for his warm per‑
sonality and quick wit, as well as his many contributions to 
neuroscience as a researcher, as a colleague, and as a friend. 
Dr. Asma Zaidi has expressed that she counts herself lucky 
for having his guidance and mentorship to fuel her passion 
for science and discovery and pushed her to greater heights 
in her work. I myself have been extremely fortunate that he 
was the first neuroscientist I worked with when I joined the 
faculty of the University of Kansas Medical Center in 2005.
Many have expressed that this dedicated issue was both 
timely and well‑deserved. The many heartfelt messages 
about Eli that we received when we inquired of potential 
contributors to this issue are a testament to his lasting influ‑
ence and the strength of his contributions to the field, and 
you may review some of these for yourself below.
Both Eli and Mary Lou Michaelis were teachers in a 
graduate-level course in pharmacology that I took during my 
doctoral studies in medicinal chemistry at the University of 
Kansas, and I fondly remember their lectures as being well 
organized, informative, and interesting. Little did I suspect 
that I would cross paths with them some 15 years later in an 
entirely different context. As an independent investigator, I 
began working on Alzheimer’s disease, and I was pleasantly 
surprised to see them at a conference run by the Alzheimer 
Drug Discovery Foundation held in New York City. We met 
more or less regularly at this conference after that, and I 
always enjoyed catching up with them personally and hear-
ing their passion for working to solve the difficult problem of 
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neurodegenerative diseases. In October of 2016, I returned 
to the University of Kansas to continue my work in this area, 
and I am extremely gratified to now have the Drs. Michaelis 
as my colleagues. I consider it a great privilege to be invited 
to contribute my latest thoughts on the molecular basis of 
Alzheimer’s disease in this special issue in honor of Prof. Eli 
Michaelis (from Michael Scott Wolfe, Ph.D.).
About 10 years ago, Elias attended the First International 
Meeting on Glutamate Dehydrogenase that we had organ-
ized on Crete. By then, we knew of his important work on 
glutamate receptors and on the glutamatergic system in gen-
eral. We also knew his pioneer work on the genetic and other 
factors that render selected brain regions and nerve cells 
vulnerable to metabolic insults, including ethanol intoxica-
tion, oxidative stress and glutamate excitotoxicity, as well 
as to the aging process. His group had created an excellent 
transgenic mouse overexpressing mouse glutamate dehy-
drogenase in neurons, a long-sought model for the study of 
aberrant glutamate metabolism. Their seminal 2009 paper 
in J Neuroscience, showing the effect of excess synaptic glu-
tamate on age-associated neurodegenerative processes, was 
a real breakthrough for us all working in the field. Elias 
presentation on Crete verified his legacy as an excellent sci-
entist and a source of inspiration for young neuroscientists. 
Indeed, during the Crete symposium he met and interacted 
with our graduate students and post-doctoral fellows, pro-
viding them with valuable insights and on how to further 
advance their carrier. Elias has a nice personality, easily 
fostering friendships. We have very fond memories of Elias 
and we consider ourselves lucky that we got to know him 
(from Andreas Plaitakis, M.D., Ph.D. and Ioannis Zaganas, 
M.D., Ph.D.).
The remarkable scientific contributions of Dr. Elias 
Michaelis and the chance to have met him at an RSA con-
gress in 1999 prompted me to apply for a postdoctoral fel-
lowship in his research laboratory. Dr. Michaelis was for 
me a fantastic mentor who instilled in me the scientific rigor 
and the desire to push his limits. I was struck by the human 
qualities of Dr. Michaelis and his way of creating the link 
between the researchers of his team to ultimately develop a 
strong sense of belonging and allow us to be proud to work 
with him. I learned a lot from him not only in terms of scien-
tific knowledge about the role of glutamate and its receptors 
in the effects of alcohol but also humanly. I was impressed 
at the time by the quality of his work and the discovery of 
new proteins forming a complex with the properties of an 
ion channel with the characteristics of a glutamate receptor 
like the NMDA receptor. In addition, like the proteins of the 
NMDA receptor, the identified proteins were also regulated 
by exposure to ethanol. Dr. Michaelis used to discuss very 
regularly with all the members of his group, to come and 
talk on the bench and to give even technical advice. At the 
end of this postdoctoral internship, the research experience 
in Dr. Michaelis’ laboratory convinced me to continue in 
the same direction and to create in France the first research 
laboratory completely dedicated to alcohol addiction. I owe 
him so much and I take this opportunity to thank him deeply 
and to show him my greatest respect (from Mickael Naassila, 
Ph.D.).
Dr. Michaelis started his career as a medical doctor with 
a goal to improve people’s health and to save lives. Following 
his instinct, he chose a life-long research career to achieve the 
goal. Over the years, he has made outstanding contributions to 
the fields of aging and neurodegeneration and continues doing 
so. For example, he reported isolation and characterization of 
cDNA for the glutamate-binding subunit of an NMDA receptor 
complex in Nature in 1991. Another outstanding contribution 
of Dr. Michaelis to the scientific research community is his 
lifetime dedication to training young scientists. Among the 
careers of his students are professors at Universities, lead-
ers of laboratories at research institutions, and experts in in 
the pharmaceutical or biotechnology industry. Furthermore, 
his outstanding leadership and excellence in mentoring have 
shaped the career of many junior faculty members at the Uni-
versity of Kansas. When asked recently how younger scientists 
deal with the current harsh funding environment, he advised 
based on his own experience that “Faith. Faith will help over-
come difficult times” (from Honglian Shi, Ph.D.).
A unique character of Dr. Elias K. Michaelis is that you 
never get bored when having a science-talk with him. I remem-
ber my interview with him for a senior postdoctoral position 
in his lab in July 1997. We had a straight 3-h conversation 
about glutamate biology, NMDA receptors and aging. Stay-
ing on the top of his field, encouraging his team members to 
tryi new methods and approaches in our studies, and some-
times working in the wet lab, showing us, for example, how 
to dissect out the hippocampus from rat brain; that partially 
describes my mentor Dr. Elias K. Michaelis. His major con-
tribution to neuroscience was to discover the brain synaptic 
membrane glutamate binding protein I worked with him in his 
three-times renewed 5 year continuously funded NIH-program 
project. I have learned a great deal of how to review grants at 
my early stage of academic career. Dr. Michaelis is not only a 
physician-scientist but also an effective critic. When the data 
presented to him in our regular lab meetings he would start 
with praise for the work done and time spent; then after that, 
he went into details and made challenges in a way that nobody 
in the room felt uncomfortable. I am using the same technique 
in my lab and my research team (Team-Q) feels that they are 
valued for their contribution as I felt in Dr. Michaelis’ lab two 
decades ago (from A. Baki Agbas, M.Sc., Ph.D.).
Dr. Elias Michaelis was devoted to a wide variety of 
research in areas of neurological disease, such as alcohol 
abuse and related brain damage, stroke, seizure neurobiology, 
and age-associated neurodegeneration. Glutamate neurotrans-
mission is the most extensive excitatory neurotransmitter in the 
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brain and spinal cord, and a key factor involved in neuronal 
excitability and neuronal death. His distinguished achieve-
ments have been due to his unceasing efforts with frontier 
spirit preparing for tomorrow. Over the past 50 years, his sci-
entific contributions on the glutamate system have been the 
main activity in the field. My individual experience with him is 
very short, but I can discern his trust and respect for scientific 
researchers in the field, including me, and that he wants to help 
those who follow him accomplish more creative works (from 
Eun Joo Baik, Ph.D.).
We at Neurochemical Research want to express our extreme 
gratitude to all its contributing authors. We are also grateful 
to be able to present this special issue in Eli’s honor, and it 
goes without saying that all of us have a deep respect for Eli’s 
body of work and hold him in the highest esteem. We hope to 
see him continue to inspire neurochemists and neuroscientists, 
both in the present and for years to come.
In‑Young Choi, Ph.D. and Arne Schousboe, D.Sc.
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